Subject: NIH GUIDE - V20(34) 09/13/91 - P1/3
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Fri, 13 Sep 91 07:40 EST

Good Morning Paul,
  This is one of several announcements and the 9/l3/9l NIH Guide
being sent this morning.  Please post to the NIH Listserver as:
      NIHGUIDE.910913
 Thanks.   Dottie
 ---------------------------- Text of forwarded message -----------------------
 
$$XID NIHGUIDE 19910913 V20N34 P1O3 ************************************
X-comment: RFAs described: CA-91-32, CA-91-33, CA-91-34, CA-91-35
 
NIH GUIDE - Vol. 20, No. 34, Part I of II, September 13, 1991
 
$$INDEX BEGIN **********************************************************
 
                                 NOTICES
 
$$INDEX N1 *************************************************************
 
BEHAVIORAL AND SOCIAL RESEARCH ON AGING
National Institute on Aging
Index:  AGING

                 NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$INDEX R1 12/31/91 ****************************************************
 
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM (RFA CA-91-32)
National Cancer Institute
Index:  CANCER
 
$$INDEX R2 01/17/91 ****************************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN BREAST CANCER (RFA CA-91-
33)
National Cancer Institute
Index:  CANCER
 
$$INDEX R3 01/17/92 ****************************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN LUNG CANCER (RFA CA-91-
34)
National Cancer Institute
Index:  CANCER
 
$$INDEX R4 01/17/92 ****************************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN PROSTATE CANCER (RFA CA-
91-35)
National Cancer Institute
Index:  CANCER

                      ONGOING PROGRAM ANNOUNCEMENTS
 
$$INDEX P1 *************************************************************
 
PREVENTION ONCOLOGY ACADEMIC AWARD (PA-91-87)
National Cancer Institute
Index:  CANCER
 
$$INDEX P2 *************************************************************
 
COURSES RELATED TO GENOMIC ANALYSIS (PA-91-88)
National Center for Human Genome Research
Index:  HUMAN GENOME
 
$$INDEX P3 *************************************************************
 
SPECIAL EMPHASIS RESEARCH CAREER AWARD IN GENOMIC RESEARCH (PA-91-89)
National Center for Human Genome Research
Index:  HUMAN GENOME
 
$$INDEX P4 *************************************************************
 
FORCASTING LIFE AND HEALTH EXPECTANCY IN OLDER POPULATIONS (PA-91-90)
National Institute on Aging
Index:  AGING
 
$$INDEX P5 *************************************************************
 
GENETICS AND FUNDAMENTAL MECHANISMS OF CHEMICAL SENSES (PA-91-91)
National Institute on Deafness and Other Communication Disorders
Index:  DEAFNESS, COMMUNICATION DISORDERS
 
$$INDEX P6 *************************************************************
 
LITERACY IN DEAF INDIVIDUALS (PA-91-92)
National Institute on Deafness and Other Communication Disorders
Index:  DEAFNESS, COMMUNICATION DISORDERS
 
$$INDEX P7 *************************************************************
 
MECHANISMS OF VOICE DISORDERS (PA-91-93)
National Institute on Deafness and Other Communication Disorders
Index:  DEAFNESS, COMMUNICATION DISORDERS
 
$$INDEX P8 *************************************************************
 
CAREER DEVELOPMENT AWARDS IN ALLERGY, IMMUNOLOGY, TRANSPLANTATION,
INFECTIOUS DISEASES AND AIDS (PA-91-94)
National Institute of Allergy and Infectious Diseases
Index:  ALLERGY, INFECTIOUS DISEASES

                                 ERRATUM
 
$$INDEX E1 *************************************************************
 
RESEARCH ON THE PREVENTION OF ALCOHOL-RELATED PROBLEMS AMONG ETHNIC
MINORITIES
National Institute on Alcohol Abuse and Alcoholism
Index:  ALCOHOL ABUSE, ALCOHOLISM
 
$$INDEX END ************************************************************
 
                                 NOTICES
 
$$N1 BEGIN *************************************************************
 
BEHAVIORAL AND SOCIAL RESEARCH ON AGING
 
P.T. 34; K.W. 040400, 0710010, 1014006
 
National Institute on Aging
 
As part of a continuing effort to build and sustain a broad program of
research on social and behavioral aspects of aging, the Behavioral and
Social Research program (BSR) of the National Institute on Aging
encourages investigators to submit applications that propose moderate
budgets and durations.
 
BSR staff continue to encourage applications in cognitive functioning
and aging, personality and social psychological aging, psychosocial
geriatrics research, older people in society, health and retirement
economics, the demography of aging, population epidemiology and related
scientific areas.
 
BSR staff can supply more information about this notice and about the
ongoing program initiatives.  Written inquiries are to be addressed to:
 
Behavioral and Social Research
National Institute on Aging
Building. 31C, Room 5C32
Bethesda, MD  20892
 
Telephone inquiries can be made to any of the BSR staff listed below.
 
Dr. Ronald Abeles
Dr. Robin Barr
Dr. Katrina Johnson
Dr. Marcia Ory
Dr. Richard Suzman
(These staff can be contacted at: 301-496-3136)
 
$$INDEX N1 END *********************************************************
 
                 NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$R1 BEGIN CA-91-32 FULL-TEXT ******************************************
 
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM
 
RFA AVAILABLE:  CA-91-32
 
P.T. 34; K.W. 0785140, 0785035
 
National Cancer Institute
 
Letter of Intent Receipt Date:  October 25, 1991
Application Receipt Date:  December 31, 1991
 
PURPOSE
 
The National Cancer Institute (NCI), through its Cancer Training Branch,
announces the availability of a Request for Applications (RFA) for
institutional physician scientist program grants that will prepare
medical doctors for clinical research careers in medical, surgical, and
radiation oncology, as well as other clinical specialties with a focus
on cancer.  The high level of support and intense activity in basic
cancer research over the past decades has resulted in the rapid growth
and constantly increasing body of knowledge about the molecular biology,
immunology, genetics, and cell biology of cancer.  However, the clinical
application of this knowledge to improve procedures that benefit cancer
patients has not kept pace with the accumulation of research results.
 
A workshop on "Training in Clinical Research in Oncology" was held on
September 12, 1990, to identify the concerns and problems facing the
clinical oncology community and to examine the adequacy of NCI training
grant mechanisms and institutional research environments for attracting
and retaining physicians in clinical oncology research.
 
There was unanimous agreement on the decline in the number of clinical
oncologists pursuing careers in innovative clinical research and a
discussion of the causes and potential solutions for reversing this
trend.  A summary was published in Cancer Research 51:  753-756, 1991.
 
The Request for Applications (RFA) is intended to stimulate the
recruitment and research career development of clinicians who will be
oriented and skilled in the translation of accumulated research results
into new clinical procedures and approaches that are of direct benefit
to cancer patients.  The NCI is initiating this new 'program'career
grant (K12) mechanism to provide excellent clinical departments and/or
cancer centers with greater flexibility in selecting and sustaining
young physicians for the critical three- to five-year period during
which these physician scientists will learn the skills needed for the
successful transition to independent grant support.
 
HEALTHY PEOPLE 2000
 
The Public Health Service is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led
national activity for setting priority areas.  This RFA, Clinical
Oncology Research Career Development Program, is related to the priority
area of cancer.  Potential applicants may obtain a copy of "Healthy
People 2000" (Full Report:  Stock No. 017-001-00474-0 or Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, D.C. 20402-9325 (telephone
202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Applications may be submitted by domestic, non-profit organizations,
whether public or private, such as universities, colleges, hospitals,
and laboratories. Applications involving minority and women students and
investigators are encouraged.
 
All candidates supported under this award must be physicians holding the
M.D. or D.O. degree.  Proposed programs must demonstrate the potential
to provide research career development opportunities in a range of
clinical oncology research disciplines and not be limited to a single
discipline.
 
MECHANISM OF SUPPORT
 
Support for this program will be through the National Institutes of
Health (NIH) grant-in-aid, the Institutional Physician Scientist Award
(K12).  Applicants will be responsible for the planning, direction, and
execution of the proposed project.  Awards will be administered under
PHS grants policy as stated in the Public Health Service Grants Policy
Statement.
 
The RFA is a one-time solicitation.  Future competitive continuation
applications will compete with all investigator-initiated applications.
Should the NCI determine that there is a sufficient continuing program
need, a request for competitive continuation and/or new applications
will be announced.  The total project period for applications submitted
in response to the present RFA may not exceed five years.  The earliest
award date will be July 1, 1992.
 
FUNDS AVAILABLE
 
Total costs of $2,700,000 will be available for the first year, $3.6
million the second year, and $4.5 million per year for the third,
fourth, and fifth years to support approximately ten awards.  This
funding level is dependent upon the receipt of a sufficient number of
applications of high scientific merit.  Although this program is
provided for in the financial plans of the NCI, the award of grants
pursuant to this RFA is also contingent upon the availability of funds
for this purpose.
 
PROJECT DESCRIPTION
 
The objectives of this RFA are to increase the number of clinical
oncologists who are motivated and properly prepared to:  (1) interact
and coordinate clinical research activities with basic research
scientists in order to expedite the translation of basic information
into patient-oriented research; (2) perform independent clinical
research that develops and tests rational, scientific hypotheses, based
on fundamental and clinical research findings, for improving the medical
care of cancer patients; and (3) design and test innovative clinical
protocols and manage all phases of clinical trials research.
 
These clinical oncology research career development programs must
involve staff and clinical candidates representing a spectrum of
clinical cancer disciplines, such as medical, surgical and radiation
oncology.  Programs limited to one clinical oncology discipline are not
responsive to the ojective of this iitiative.  Interaction during these
arly years of career training might serve t enhance the knds of
coordination and team approach necessary for optimum cancer patient
care.
 
Applicants must propose a program that is designed to provide clinician
candidates with the research skills that deal directly with aspects of
cancer detection, diagnosis, prognosis, and treatment of cancer
patients.  It is expected that these clinical oncology career
development programs will include both a didactic component (e.g.,
formal courses, lecture series, seminars, and journal clubs) and a
research component that focuses on the skills necessary for translating
basic cancer research results into clinical experiments, procedures, and
trials directly involving cancer patients in a clinical environment.
For example, it will not be sufficient within the scope of this
initiative to use human cells and other clinical materials in an
isolated basic laboratory setting as the total research development
program.  Basic laboratory research experience is essential, but it must
be properly integrated with clinical research.
 
The proposed program must have the flexibility to accommodate clinical
candidates with different levels of research competence.  While the end
goal of this program is specifically to prepare physicians for dedicated
careers in clinical oncology  research, not basic research, candidates
must be or become competent in the fundamentals of the scientific
method, particularly hypothesis development, experimental design, and
biostatistical methods that are usually gained through a significant
hands-on basic research experience.  In most cases, candidates would
acquire both basic and clinical research skills that will prepare them
to become dedicated clinical researchers able to interact and
communicate effectively with basic research scientists in the design and
implementation of collaborative research involving patients.
 
SPECIAL REQUIREMENTS
 
The Principal Investigator must establish an advisory committee
consisting of accomplished medical, surgical, and radiation oncologists
and other clinical cancer and basic research investigators.
 
Each clinical research candidate must have one or more
preceptor/mentor(s) who are accomplished investigators in their field.
 
Plans for an annual evaluation of the program must be described and a
summary of this evaluation must be included in the Annual Progress
Report for the grant.
 
An active institutional (T32) National Research Service Award (NRSA)
supporting a surgical or other clinical oncology research training
program already exists.  The applicant must address the relationship
between the existing T32 and proposed K12 programs.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in study
populations.  If women or minorities are not included in the study
populations for clinical studies, a specific justification for this
exclusion must be provided.  Applications without such documentation
will not be accepted for review.
 
APPLICATION PROCEDURES
 
The most recent revision of the regular research grant application form
PHS 398 (rev. 10/88) must be used in applying for these grants.  These
forms are available at most institutional business offices and from:
 
Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building, Room 449
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-7441
 
Applications must be received by December 31, 1991. The RFA contains
complete application procedures.
 
LETTER OF INTENT
 
Although not required, a letter of intent is requested by October 25,
1991, that  includes a descriptive title of the proposed educational
program, the name and address of the Principal Investigator, names of
other key personnel, participating institutions, and the number and
title of the RFA.  The letter of intent is to be sent to the program
official named below.
 
Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, it is requrested
in order to provide an indication of the number of scope of applications
to be reviewed.
INQUIRIES
 
Written and telephone inquiries concerning the objectives and scope of
RFAs are encouraged.  The opportunity to clarify any issues or questions
from potential applicants is welcomed.  The program official named below
will be   pleased to mail the complete RFA to all who request it.
 
Direct inquiries regarding programmatic issues to:
 
Dr. Vincent J. Cairoli
Chief, Cancer Training Branch
National Cancer Institute
Executive Plaza North, Room 232
Bethesda, MD 20892
Telephone:  (301) 496-8580
FAX:  (301) 402-0181
 
Direct inquiries regarding grants management issues to:
 
Mr. Robert Hawkins
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 242
Bethesda, MD  20892
Telephone:  (301) 496-7800, extension 13
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic Assistance
No. 93.398, Cancer Research Manpower.  Awards are made under
authorization of the Public Health Service Act, Title IV, Part A (Public
Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and
administered under PHS grants policies and Federal Regulations 42 CFR 52
and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.
 
$$R1 END ***************************************************************
 
$$R2 BEGIN CA-91-33 FULL-TEXT ******************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN BREAST CANCER
 
RFA AVAILABLE:  CA-91-33
 
P.T. 34; K.W. 07150350, 710030, 0745027, 0745070
 
National Cancer Institute
 
Letter of Intent Receipt Date:  October 25, 1991
Application Receipt Date:  January 17, 1992
 
PURPOSE
 
The Organ Systems Coordinating Branch of the Division of Cancer Biology,
Diagnosis and Centers at the National Cancer Institute (NCI) announces
the availability of a Request for Applications (RFA) for grants to
establish Specialized Programs of Research Excellence in Breast Cancer
(P50) at institutions that will make strong commitments to the
organization and conduct of these programs.  Each Specialized Program of
Research Excellence (SPORE) must be dedicated to translational research
on prevention, diagnosis, and treatment of human breast cancer.
Translational research moves basic research findings to applied
innovative research with patients and populations. This may include
areas such as the development of new diagnostic and prognostic tests,
the conduct of innovative therapeutic protocols, the development of new
primary and secondary prevention measures, as well as control studies
and studies that encompass rehabilitation and quality-of-life research.
Each SPORE must (1) provide career development opportunities for
independent investigators who wish to pursue active research careers in
translational breast cancer research; (2) develop and maintain human
breast cancer tissue resources that will benefit translational research;
(3) develop extended collaborations in critical areas of research need
with laboratory and clinical scientists in the parent institution and in
other institutions; and (4) participate with other SPOREs on an annual
basis to share information, assess scientific progress in the field, and
identify new research opportunities for reducing breast cancer incidence
and mortality, and for increasing and improving survival.  Each SPORE
must support a mix of basic and clinical research. The SPORE mechanism
is not intended to support basic research to the exclusion of clinical
or applied research; it must focus on human disease and effectively move
basic research findings into applied research settings with patients and
populations, as well as take advantage of observations from applied
research to stimulate new basic research.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000," a
PHS-led national activity for setting priority areas.  This Request For
Application, Specialized Program of Research Excellence (SPORE) in
Breast Cancer, is related to the priority area of cancer.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock NO. 017-001-004740-0 or Summary Report No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, D.C. 20402-9325 (telephone 202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Domestic non-profit and for-profit organizations, institutions, and
government agencies are eligible to apply.  To be eligible, applicant
organizations must have a minimum of three independent investigators who
are successful in obtaining peer-reviewed research support directly
related to breast cancer, and who combined represent experience in both
laboratory and clinical research; access to a patient care and service
facility that serves breast cancer patients. Applications may be
submitted from a single institution or may include arrangements with
multiple institutions, e.g., consortia, as appropriate.
 
MECHANISM OF SUPPORT
 
Support of this program will be through the P50 Specialized Center Grant
mechanism.  Applicants will be responsible for the planning, direction,
and execution of the proposed SPORE program.  Except as otherwise noted
in this RFA, awards will be administered under PHS grants policy as
stated in the Public Health Service Grants Policy Statement.
 
This RFA is a one-time solicitation.  The total project period for
applications submitted in response to the present RFA may not exceed
three years.  The anticipated award date will be September 30, 1992.
 
FUNDS AVAILABLE
 
The NCI anticipates making up to three awards for initial project
periods of three years and anticipates that a total of $7.5 million will
be set aside for the initial year's funding.  Funding in response to
this RFA is dependent upon the receipt of a sufficient number of
applications of high scientific merit.  Although this program is
provided for in the financial plans of the NCI, the award of grants
pursuant to this RFA is contingent upon the availability of funds for
this purpose.  NCI policy for SPORE grants establishes the following
limits to the requested budgets: up to $1.5 million direct costs in the
01 year with a maximum four percent annual escalation in the remaining
years proposed.
 
GOALS AND SCOPE
 
The goal of this RFA is to establish three SPOREs, which will assemble
critical masses of laboratory and clinical scientists working together
to focus on human breast cancer and the translation of basic findings
into applied, innovative research with patients and populations.  The
ultimate objective is to reduce incidence and mortality, and to increase
and improve survival to the disease.  The essential characteristics of a
SPORE include (1) a strong scientific program that will have a clear
impact on the disease, (2) a strong innovative pilot research program
that can respond quickly to new research opportunities, (3) a strong
career development program to develop and expand the scientific cadre of
investigators dedicated to translational research on human breast
cancer, and (4) a human breast cancer tissue procurement resource and
other resources specifically dedicated to translational research
objectives.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES.
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in study
populations.  Although the applicability of women to this RFA is
obvious, the requirement to address minorities must be addressed.  If
minorities are not included in the study populations for clinical
studies, a specific justification for this  exclusion must be provided.
Applications without such documentation will not be accepted for review.
 
APPLICATION PROCEDURES
 
The research grant application form PHS 398 (revised 10/88) must be used
in applying for these grants.  Applications must be received by January
17, 1992; those received after that date will be returned.  Further
information regarding application procedures and application forms may
be obtained from the NCI Program Director named below.
 
LETTER OF INTENT
 
Prospective applicants are asked to submit by October 25, 1991, a letter
of intent that includes the name and address of the principal
investigator and identifies the component research projects, core units
and their principal investigators, any collaborating institutions, and
the number and title of the RFA in response to which the application is
being submitted.  Although a letter of intent is not required, is not
binding, and does not enter into the review of subsequent applications,
it provides an indication of the number and scope of the applications to
be reviewed.  The letter of intent is to be sent to Dr. Andrew Chiarodo
(see INQUIRIES below).
 
INQUIRIES
 
This is an abbreviated version of the RFA.  Copies of the complete RFA
and additional information concerning the objectives and scope of this
RFA may be obtained from:
 
Andrew Chiarodo, Ph.D.
Chief, Organ Systems Coordinating Branch
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
9000 Rockville Pike
Executive Plaza North, Suite 316
Bethesda, MD  20892
Telephone:  (301) 496-8528
FAX:  (301) 402-0181
 
For fiscal or administraive matters, contact:
 
Robert E. Hawkins
Grants Management Specialist
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 216
Bethesda, MD  20892
Telephone:  (301) 496-7800 ext. 13
 
For fiscal or administrative matters, contact:
 
Robert E. Hawkins
Grants Management Specialist
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 216
Bethesda, MD  20892
Telephone:  (301) 496-7800
 
AUTHORITY AND REGULATIONS
 
This program is described in the catalog of Federal Domestic Assistance
No. 93.397.  Awards are under authorization of the Public Health Service
Act, Title IV, Part A (Public Law 78-410 as amended:  42 USC 241) and
administered under PHS grants policies and Federal Regulations 42 CFR
Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.
 
$$R2 END ***************************************************************
 
$$R3 BEGIN CA-91-34 FULL-TEXT ******************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN LUNG CANCER
 
RFA AVAILABLE:  CA-91-34
 
P.T. 34; K.W. 0715035, 0715165
 
National Cancer Institute
 
Letter of Intent Receipt Date:  October 25, 1991
Application Receipt Date:  January 17, 1992
 
PURPOSE
 
The Organ Systems Coordinating Branch of the Division of Cancer Biology,
Diagnosis and Centers at the National Cancer Institute (NCI) to
establish Specialized Programs of Research Excellence (P50) in Lung
Cancer at institutions that will make strong commitments to the
organization and conduct of these programs.  Each Specialized Program of
Research Excellence (SPORE) must be dedicated to translational research
on prevention, diagnosis, and treatment of human lung cancer.
Translational research moves basic research findings to applied
innovative research with patients and populations. This may include
areas such as the development of new diagnostic and prognostic tests,
the conduct of innovative therapeutic protocols, the development of new
primary and secondary prevention measures, as well as control studies
and studies that encompass rehabilitation and quality-of-life research.
The SPORE must (1) foster basic and clinical research collaborations;
(2) provide career development opportunities for independent
investigators who wish to pursue active research careers in lung cancer
research; (3) develop and maintain human lung cancer tissue resources;
(4) participate with other lung SPOREs on an annual basis in sharing
information and assessing scientific progress; (5) develop extended
collaborations and interactions with scientists and clinicians in other
institutions.  It is expected that each SPORE will support a mix of
basic and clinical research.  The SPORE mechanism is not intended to
support basic research to the exclusion of clinical or applied research.
It must focus on human disease and the application of basic research to
patients and populations as well as take advantage of observations from
applied research to stimulate new basic research.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000," a
PHS-led national activity for setting priority areas.  This Request For
Application, Specialized Program of Research Excellence (SPORE) in Lung
Cancer, is related to the priority area of cancer.  Potential applicants
may obtain a copy of "Healthy People 2000" (Full Report:  Stock No. No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, D.C. 20402-9325 (telephone 202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Domestic non-profit and for-profit organizations, institutions, and
government agencies are eligible to apply.  To be eligible, applicant
organizations must have a minimum of three independent investigators who
are successful in obtaining peer-reviewed research support directly
related to lung cancer and who as a group represent experience in both
laboratory and clinical research; access to a patient care and service
facility that serves lung cancer patients.  Applications may be
submitted from a single institution or may include arrangements with
several institutions, e.g., consortia, as appropriate.
 
MECHANISM OF SUPPORT
 
Support of this program will be through the P50 Specialized Center Grant
mechanism.  Applicants will be responsible for the planning, direction,
and execution of the proposed SPORE program.  Except as otherwise noted
in this RFA, awards will be administered under PHS grants policy as
stated in the Public Health Service Grants Policy Statement.
 
This RFA is a one-time solicitation.  The total project period for
applications submitted in response to the present RFA must not exceed
three years.  The anticipated award date will be September 30, 1992.
 
FUNDS AVAILABLE
 
The NCI anticipates making up to three awards for initial project
periods of three years and anticipates that a total of $7.5 million will
be set aside for the initial year's funding.  Funding in response to
this RFA is dependent upon the receipt of a sufficient number of
applications of high scientific merit.  Although this program is
provided for in the financial plans of the NCI, the award of grants
pursuant to this RFA is contingent upon the availability of funds for
this purpose.  NCI policy for SPORE grants establishes the following
limits to the requested budgets: up to $1.5 million direct costs in the
01 year with a maximum 4 percent annual escalation in the remaining
years proposed.
 
GOALS AND SCOPE
 
The goal of this RFA is to establish three SPOREs, that will assemble
enough laboratory and clinical scientists working together on human lung
cancer to be able to translate basic findings into applied, innovative
research with patients and populations.  The ultimate objective is to
reduce incidence and mortality and to increase and improve survival to
the disease.  The essential characteristics of a SPORE include (1) a
strong scientific program that will have a clear impact on the disease,
(2) a strong innovative pilot research program that can respond quickly
to new research opportunities, (3) a strong career development program
to develop and expand the scientific cadre of investigators dedicated to
translational research on human lung cancer, and (4) a human lung cancer
tissue procurement resource and other resources specifically dedicated
to translational research objectives.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES.
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in study
populations.  If women or minorities are not included in the study
populations for clinical studies, a specific justification for this
exclusion must be provided.  Applications without such documentation
will not be accepted for review.
 
APPLICATION PROCEDURES
 
The most recent revision of the research grant application form PHS 398
(revised 10/88) must be used in applying for these grants.  Applications
must be received by January 17, 1992; those received after that date
will be returned. Further information regarding application procedures
and application forms may be obtained from the NCI Program Director
named below.
 
LETTER OF INTENT
 
Prospective applicants are asked to submit by October 25, 1991, a letter
of intent that includes the name and address of the Principal
Investigator and identifies the component research projects, core units
and their principal investigators, any collaborating institutions, and
the number and title of the RFA in response to which the application is
being submitted.  Although a letter of intent is not required, is not
binding, and does not enter into the review of subsequent applications,
it provides an indication of the number and scope of the applications to
be reviewed.  The letter of intent is to be sent to Dr. Andrew Chiarodo
(see INQUIRIES below).
 
INQUIRIES
 
This is an abbreviated version of the RFA.  Copies of the complete RFA
and additional information concerning the objectives and scope of this
RFA may be obtained from:
 
Andrew Chiarodo, Ph.D.
Chief, Organ Systems Coordinating Branch
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
9000 Rockville Pike
Executive Plaza North, Suite 316
Bethesda, MD  20892
Telephone: (301) 496-8528
FAX: (301) 402-0181
 
For fiscal and administrative matters, contact:
 
Robert E. Hawkins
Grant Management Specialist
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 216
Bethesda, MD  20892
Telephone:  (301) 496-7800 ext. 13
 
AUTHORITY AND REGULATIONS
 
This program is described in the catalog of Federal Domestic Assistance
No.  93.397.  Awards are made under authorization of the Public Health
Service Act, Title IV, Part A (Public Law 78-410 as amended:  42 USC
241) and administered under PHS grants policies and Federal Regulations
42 CFR Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.
 
$$R3 END ***************************************************************
 
$$R4 BEGIN CA-91-35 FULL-TEXT ******************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN PROSTATE CANCER
 
RFA AVAILABLE:  CA-91-35
 
P.T. 34; K.W. 0715030, 0715167
 
National Cancer Institute
 
Letter of Intent Receipt Date:  October 25, 1991
Application Receipt Date:  January 17, 1992
 
PURPOSE
 
The Organ Systems Coordinating Branch of the Division of Cancer Biology,
Diagnosis, and Centers at the National Cancer Institute (NCI) announces
the availability of a Request for Applications (RFA) for grants to
establish Specialized Programs of Research Excellence in Prostate Cancer
at institutions that will make strong commitments to the organization
and conduct of these programs.  Each Specialized Program of Research
Excellence (SPORE) must be dedicated to state-of-the-art research in the
biology of prostate cancer as well as prevention, diagnosis, and
treatment of the disease; rehabilitation and quality-of-life research
may also be pursued.  The SPORE must (1) foster basic and clinical
research collaborations; (2) develop and maintain human prostate cancer
tissue resources; (3) develop and improve animal models for prostate
cancer research; (4) provide career development opportunities for
independent investigators who wish to pursue active research careers in
prostate cancer research; (5) participate with other SPOREs on an annual
basis to share information, assess scientific progress, and identify new
research opportunities for reducing incidence and mortality, and for
increasing and improving survival; and (6) develop extended
collaborations in critical areas of research need with laboratory and
clinical scientists in the parent institution and in other institutions.
Each SPORE must support a mix of basic and clinical research.  The SPORE
mechanism is not intended to support basic research to the exclusion of
clinical or applied research; it is expected to effectively move basic
research findings to applied research with patients and populations and
to use observations from applied research to stimulate new basic
research.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000," a
PHS-led national activity for setting priority areas.  This Request For
Application, Specialized Program of Research Excellence (SPORE) in
Prostate Cancer, is related to the priority area of cancer.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, D.C. 20402-9325 (telephone
202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Domestic non-profit and for-profit organizations, institutions, and
government agencies are eligible to apply.  To be eligible, applicant
organizations must have a minimum of three independent investigators who
are successful in obtaining peer-reviewed research support directly
related to prostate cancer, and who as a group represent experience in
both laboratory and clinical research and access to a patient care and
service facility that serves prostate cancer patients.  Applications may
be submitted from a single institution or may include arrangements with
several institutions, e.g., consortia, as appropriate.
 
MECHANISM OF SUPPORT
 
Support of this program will be through the P50 Specialized Center Grant
mechanism.  Applicants will be responsible for the planning, direction,
and execution of the proposed SPORE program.  Except as otherwise noted
in this RFA, awards will be administered under PHS grants policy as
stated in the Public Health Service Grants Policy Statement.
 
The RFA is a one time solicitation.  The total project period for
applications submitted in response to the present RFA must not exceed
three years.  The anticipated award date will be September 30, 1992.
 
FUNDS AVAILABLE
 
The NCI anticipates making up to three awards for initial project
periods of three years and anticipates that a total of $7.5 million will
be set aside for the initial year's funding.  Funding in response to
this RFA is dependent upon the receipt of a sufficient number of
applications of high scientific merit.  Although this program is
provided for in the financial plans of the NCI, the award of grants
pursuant to this RFA is contingent upon the availability of funds for
this purpose.  NCI policy for SPORE grants establishes the following
limits to the requested budgets: up to $1.5 million direct costs in the
01 year with a maximum 4 percent annual escalation in the remaining
years proposed.
 
GOALS AND SCOPE
 
The goal of this RFA is to establish three SPOREs that will assemble
critical masses of laboratory and clinical scientists working together
to expand the research base in prostate cancer and to translate the
basic research findings to applied innovative research with patients and
populations.  The ultimate objective is to increase and improve survival
and to reduce incidence and mortality to the disease.  The essential
characteristics of a SPORE include (1) a strong scientific program that
will have a clear impact on the disease, (2) a strong innovative pilot
research program that can respond quickly to new research opportunities,
(3) a strong career development program to develop and expand the
scientific cadre of investigators dedicated to research on prostate
cancer, and (4) a human prostate cancer tissue procurement resource, an
animal model resource, and other resources specifically dedicated to
prostate cancer research.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES.
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in study
populations.  While inclusion of women is not relevant to this RFA, the
requirement to address minorities must be addressed.  If minorities are
not included in the study populations for clinical studies, a specific
justification for this exclusion must be provided.  Applications without
such documentation will not be accepted for review.
 
APPLICATION PROCEDURES
 
The most recent revision of the research grant application form PHS 398
(revised 10/88) must be used in applying for these grants.  Applications
must be received by January 17, 1992; those received after that date
will be returned.  Further information regarding application procedures
and application forms may be obtained from the NCI Program Director
named below.
 
LETTER OF INTENT
 
Prospective applicants are asked to submit by October 25, 1991, a letter
of intent that includes the name and address of the Principal
Investigator and identifies the component research projects, core units
and their principal investigators, any collaborating institutions, and
the number and title of the RFA in response to which the application is
being submitted.  Although a letter of intent is not required, is not
binding, and does not enter into the review of subsequent applications,
it provides an indication of the number and scope of the applications to
be reviewed.  The letter of intent is to be sent to Dr. Andrew Chiarodo
(see INQUIRIES below).
 
INQUIRIES
 
This is an abbreviated version of the RFA.  Copies of the complete RFA
and additional information concerning the objectives and scope of this
RFA may be obtained from:
 
Andrew Chiarodo, Ph.D.
Chief, Organ Systems Coordinating Branch
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
9000 Rockville Pike
Executive Plaza North, Suite 316
Bethesda, MD  20892
Telephone:  (301) 496-8528
FAX:  (301) 402-0181
 
For fiscal or administrative matters, contact:
 
Robert E. Hawkins
Grants Management Specialist
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 216
Bethesda, MD  20892
Telephone:  (301) 496-7800
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic Assistance
No.  913.397.  Awards are under authorization of the Public Health
Service Act, Title IV, Part A (Public Law 78-410 as amended:  42 USC
241) and administered under PHS grants policies and Federal Regulations
42 CFR Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.
 
$$R4 END ***************************************************************
 
                      ONGOING PROGRAM ANNOUNCEMENTS
 
$$P1 BEGIN PA-91-87 ****************************************************
 
PREVENTIVE ONCOLOGY ACADEMIC AWARD
 
PA:  PA-91-87
 
P.T. 34; K.W. 0715035, 0745027, 0785140
 
National Cancer Institute
 
Application Receipt Dates:  February 1, June 1, October 1
 
PURPOSE
 
The National Cancer Institute (NCI) invites submission of applications
from individuals who hold a Ph.D., M.D., or similar professional degree
for career development awards in cancer prevention.  Subject areas
appropriate for awards under this program announcement include
cancer-related aspects of human genetics, human nutrition, behavioral
and social sciences, biochemical and genetic epidemiology, prevention
clinical trials, health education and promotion, nursing, and public
health.  The proposed research must be directly applicable and relevant
to cancer prevention and control.
 
The scope of the candidate's career training research projects may
extend from the development and testing of hypotheses concerning cancer
prevention, the design and implementation of interventions in defined
populations, to a large-scale demonstration project.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000," a
PHS-led national activity for setting priority areas.  This program
announcement, Preventive Oncology Academic Award, is related to the
priority area of Cancer.  Potential applicants may obtain a copy of
"Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0) or
Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, D.C. 20402-9325 (telephone 202-783-3238).
 
OBJECTIVES
 
The primary objective of this program is to train professionals in
research techniques necessary for the development and implementation of
interventions designed to prevent cancer and to improve the early
detection and diagnosis of cancer.  Of special interest is training that
focuses on the definition of high-risk groups and on new methods of
intervention that will reduce cancer incidence and mortality in these
groups.
 
Personnel trained under this career program are expected to have a
significant impact on cancer prevention and control research efforts,
especially in projects designed to:  (1) increase participation in
programs that may result in earlier detection and diagnosis of cancer,
particularly in special populations with increased cancer risk (e.g.,
ethnic groups, minority groups, and groups with low socioeconomic
status); and (2) prevent cancer by the modification of behaviors and
life-styles related to increased cancer risk (e.g., tobacco use, altered
diet).
 
A secondary objective is to strengthen the preventive oncology and
research career education programs at institutions that sponsor these
academic awards (KO7).
 
MECHANISM OF SUPPORT
 
This program announcement will provide awards through the existing
Preventive Oncology Academic Award (K07) grant mechanism.  Each award
will be made for a total project period of three to five years depending
on the applicant's background, needs, and objectives.
 
ELIGIBILITY
 
The candidate must be a citizen or permanent resident of the United
States, hold a doctorate level degree (e.g., M.D., Ph.D., D.O.), and
have at least two years of postgraduate experience.
 
The major target group for this award includes professionals already
proficient in clinical oncology, general epidemiology, psychology,
behavioral sciences, or other pertinent sciences who wish to make the
transition to a career in cancer prevention and control research.  Also
included are other professionals who already have some training in
cancer prevention and control but who need to gain additional
professional experience that will permit them to become fully
independent investigators.
 
Applications may be submitted by individuals who are affiliated with
public or private entities such as universities, colleges, hospitals,
laboratories, units of State or local governments and eligible agencies
of the Federal Government.  Applications from minority individuals and
women are encouraged.  This award also provides an optional opportunity
to trainees who wish to participate in prevention and control research
projects at the for three months or more.
 
The candidate must have a teaching or research appointment with the
sponsoring institution at the time the award is made and devote
full-time (at least 80 percent) to this award.  An institution
sponsoring a candidate for the award must show commitment to developing
and improving the teaching of prevention of cancer, commit educational
resources for the training, grant time for the awardee to acquire
educational skills, and provide facilities for research.
 
STUDY POPULATIONS
 
It is the NIH policy that women and minorities must be included in
clinical study populations unless there is a good reason to exclude
them, and the study design must seek to identify any pertinent gender or
minority population differences.
 
SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS
 
NIH policy is that applicants for NIH grants will be required to include
minorities and women in study populations so that research findings can
be of benefit to all persons at risk of the disease, disorder or
condition under study; special emphasis should be placed on the need for
inclusion of minorities and women in studies of diseases, disorders and
conditions which disproportionately affect them.  This policy is
intended to apply to males and females of all ages.  If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale should be provided.
 
The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research design
and sample size appropriate for the scientific objectives of the study.
This information should be included in the form PHS 398 in Section 2,
A-D of the Research Plan AND summarized in Section 2, E, Human Subjects.
Applicants/offerors are urged to assess carefully the feasibility of
including the broadest possible representation of minority groups.
However, NIH recognizes that it may not be feasible or appropriate in
all research projects to include representation of the full array of
United States racial/ethnic minority populations (i.e., Native Americans
(including American Indians or Alaskan Natives), Asian/Pacific
Islanders, Blacks, Hispanics).  The rationale for studies on single
minority population groups should be provided.
 
For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and preventive strategies), diagnosis, or treatment of diseases,
disorders or conditions, including but not limited to clinical trials.
 
The usual NIH policies concerning research on human subjects also apply.
Basic research clinical studies in which human tissues cannot be
identified or linked to individuals are excluded.  However, every effort
should be made to include human tissues from women and racial/ethnic
minorities when it is important to apply the results of the study
broadly, and this should be addressed by applicants.
 
If the required information is not contained within the application, the
review will be deferred until the information is provided.
 
Peer reviewers will address specifically whether the research plan in
the application conforms to these policies. If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.
All applications for clinical research submitted to NIH are required to
address these policies.  NIH funding components will not award grants
for cooperative agreements that do not comply with these policies.
 
APPLICATIONS PROCEDURES
 
Applicants are encouraged to obtain copies of program guidelines
containing further requirements from:
 
Program Director
Cancer Training Branch
National Cancer Institute
Executive Plaza North, Room 232
9000 Rockville Pike
Bethesda, MD  20892
 
The most recent revision of the research grant application form PHS 398
(rev. 10/88) must be used. These forms are available at most
institutional business offices; from the Office of Grants Inquiries,
Division of Research Grants, National Institutes of Health, Room 449,
Westwood Building, 5333 Westbard Avenue, Bethesda, MD 20892, telephone
(301) 496-7441.
 
Complete line 2 of the application face page of the PHS 398 by inserting
the title and number of this announcement, "Preventive Oncology Academic
Award, PA-91-87."
 
Submit a signed, typewritten original of the application including the
Checklist and four signed, exact photocopies in one package to the
address below.  The photocopies must be clear and single sided.
 
DIVISION OF RESEARCH GRANTS
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
 
At time of submission, send two additional copies of the application to:

REFERRAL OFFICER
Division of Extramural Activities
National Cancer Institute
Westwood Building, Room 838
5333 Westbard Avenue
Bethesda, MD  20892
 
REVIEW PROCEDURES AND CRITERIA
 
Applications will be assigned on the basis of established Public Health
Service referral guidelines.  Applications will be reviewed for
scientific and technical merit by a study section convened by the
Division of Extramural Activities, NCI, in accordance with the usual NIH
peer review procedures.  Following scientific-technical review, the
applications will receive a second-level review by the National Cancer
Advisory Board.
 
Applications will be reviewed for the candidate's commitment to and
potential for a career focusing on cancer prevention and control,
excellence of the proposed research project, the potential for
development of new research skills, the qualifications of the proposed
sponsor, and the availability of appropriate facilities and resources
for the training.
 
Applications will compete for available funds with all other approved
applications assigned to the NCI.  The following will be considered in
making funding decisions:  o Quality of the proposed project as
determined by peer review
 
o Program balance among research areas of the announcement
 
o Availability of funds
 
INQUIRIES
 
Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.
 
Direct inquiries regarding programmatic issues to:
 
Dr. John Schneider or Dr. Andrew Vargosko
Cancer Training Branch
National Cancer Institute
Executive Plaza North, Room 232
Bethesda, MD  20892
Telephone:  (301) 496-8580
 
Direct inquiries regarding fiscal matters to:
 
Mr. Robert Hawkins
Team Leader, Grants Administration Branch
National Cancer Institute
National Institutes of Health
Executive Plaza South, Room 242
Bethesda, MD  20892
Telephone:  (301) 496-7800, extension 13
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic Assistance
No. 93.398.  Awards are made under authorization of the Public Health
Service Act, Title IV, Part A (Public Law 78-410, as amended by Public
Law 99-158, 42 USC 241 and 285) and administered under PHS grants
policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74.  This
program is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.
 
$$P1 END ***************************************************************
 
$$P2 BEGIN PA-91-88 ****************************************************
 
COURSES RELATED TO GENOMIC ANALYSIS
 
PA:  PA-91-88
 
P.T. 34; K.W. 1215018, 0502000, 0755045, 0755035
 
National Center for Human Genome Research
 
The National Center for Human Genome Research (NCHGR) invites
applications for support of short, advanced-level courses in genomic
analysis.  Of particular interest are courses that emphasize new
laboratory techniques in genetic and physical mapping; DNA sequencing
technology applicable to large-scale projects; informatics as it relates
to the Human Genome Program; and interdisciplinary training in
principles of genomic analysis for non-biologists and principles and
methods of studying the ethical, legal, and social issues relevant to
the Human Genome Program for biologists.  These courses are meant to
enhance the skills of individuals who are already involved in or are
interested in pursuing laboratory or scholarly research relevant to the
goals of the Human Genome Program.
 
BACKGROUND
 
The National Institutes of Health, in coordination with several other
Federal, private, and international organizations, is currently engaged
in a research program designed to characterize the genomes of the human
and selected model organisms.  As outlined in a five-year plan recently
prepared in conjunction with the Department of Energy and available from
the Human Genome Management Information Center, Oak Ridge National
Laboratory, Oak Ridge, TN  37831-6050, telephone number (615) 576-6669,
the initial objectives of the Human Genome Program include the
construction of a high-resolution genetic linkage map of the human, the
development of detailed physical maps of both the human genome and the
genomes of model organisms, and the improvement of technology for
genetic and physical mapping, DNA sequencing, and data management.  The
longer-term goals of the program include determination of the human DNA
sequence and the sequences of the DNA of important model organisms and
ultimately the identification of all the genes.  An additional important
objective throughout the entire course of the research program is the
analysis of the ethical, legal, and social policy issues that are raised
by the availability of such detailed genetic information.  The expected
outcomes of the Human Genome Program are a set of research tools,
comprising both materials and information, that will improve the
capability and efficacy of a wide range of biological and biomedical
research, as well as guidelines, recommendations, and policies for the
introduction of this new information into medical practice.
 
For the genome project and the field of genomic research to develop
rapidly enough to meet these goals in a timely and cost-effective
manner, it will be necessary to disseminate technological advances and
new information as rapidly as possible and to recruit scientists from
many disciplines, both biological and non-biological, into this research
area. The development of many fields, such as molecular biology and
genetics, has been enormously abetted by the availability of short,
intensive, advanced-level courses.  Properly designed courses in areas
of relevance to genomic analysis could be of similar utility to the
development of the genome project itself and to the application of the
information produced by the project.
 
RESEARCH OBJECTIVE
 
The goal of this program announcement is to stimulate the development of
courses in subjects relevant to the Human Genome Program and appropriate
to the broader scientific community.  The objective of each course must
be to provide participants with up-to-date knowledge of the latest
technological advances so that they can participate more effectively in
the Human Genome Program or utilize the information and technology
produced by the Human Genome Program in other areas of research.
 
Although grants have already been awarded for a number of courses, the
NCHGR is still interested in receiving applications for courses in all
areas of genomic analysis.  The following list of potential subjects for
such courses is not intended to be limiting, but to provide examples:
 
o Important laboratory techniques applicable to physical and/or genetic
mapping studies, emphasizing new technological developments relevant to
genomic analysis.  Examples include: in situ fluorescence cytogenetics;
microdissection and other new marker development techniques,
particularly those that are PCR-based; use of large-fragment cloning
vectors such as yeast artificial chromosomes; and linkage analysis.
Courses of this type must be addressed to practicing biologists who want
to learn new methodologies.
 
o Large-scale DNA sequencing, emphasizing analysis and discussion of
problems to be solved, particular strategies, and the most up-to-date
technology applicable to large-scale DNA sequencing.  Large-scale
sequencing courses must include:  template preparation; sequencing;
collection, assembly, and preliminary analysis of sequence data; and
automation of these steps.  These courses must be at an advanced level
and designed for scientists who already have experience in some aspect
of DNA sequencing.
 
o Courses that introduce the principles of genome analysis to
non-biological scientists such as mathematicians, statisticians,
physicists, chemists, engineers, and computer and information scientists
in order to stimulate the application of state-of-the-art methodologies
to current data management and analysis problems.  These courses must
describe current experimental, analytical, and data management
methodology as an introduction to a review of current problems.  These
courses are designed to stimulate interdisciplinary research
collaborations between mathematical or computer scientists and genome
researchers.
 
o Various aspects of informatics relevant to large-scale genetic and
physical mapping and sequencing projects. Examples include:  database
design, data analysis for map and/or sequence assembly, and data
management.  Such courses must be addressed to scientists who are
presently involved in mapping and sequencing projects.
 
o Techniques relevant to the analysis of the ethical, legal, and social
implications of human genome research and their application to genomic
data.  Examples include courses designed to introduce scholars trained
in the humanities, social sciences, and law to the science underlying
genomic research and to introduce biologists and health professionals to
legal, philosophical, and social scientific approaches. Courses in the
principles and methods of particular disciplines, such as insurance
economics and patent law, that are relevant to specific uses of new
genetic knowledge are also encouraged.
 
Plans for the inclusion of individuals who are currently
underrepresented in the field of genomic research, such as women and
underrepresented minorities, should be addressed.
 
Course terms may range from a few days to a few weeks and may be offered
annually, although other terms will be acceptable. Applicants may
request support for two years. Faculty must consist of established
investigators or scholars actively working in the area of instruction.
 
ELIGIBILITY
 
Course offerors are expected to be academic or research institutions
experienced in training.  However, applications from for-profit
institutions will also be accepted. Only domestic institutions are
eligible to apply for support under this announcement.
 
MECHANISM OF SUPPORT
 
Support for this program will be through the Continuing Education
Training Grant mechanism (T15).  Allowable costs include personnel,
supplies, travel, and per diem for faculty and other costs, such as
printing, telephone, audio-visual, postage, recruitment materials, and
funds for a limited number of scholarships.  The indirect cost rate for
T15 awards is eight percent, excluding equipment, tuition, and fees.
Although it is envisioned that applicant institutions will have the
necessary equipment to support course offerings, the NCHGR will
consider, on a limited basis, requests for equipment, if properly
justified.  Justification for equipment that is to be purchased rather
than rented must be provided.  It is also expected that the courses will
be partially supported through registration fees paid for by
participants.
 
APPLICATION AND REVIEW PROCEDURES
 
Applications received in response to this announcement will be reviewed
in accordance with the usual NIH peer review procedures.  Potential
applicants are encouraged to discuss the plans and objectives of their
proposed courses with NCHGR staff before developing their applications.
 
If the application submitted in response to this program announcement is
substantially similar to a grant application already submitted to the
NIH for review, but which has not yet been reviewed, the applicant will
be asked to withdraw either the pending application or the new one.
Simultaneous submission of identical applications will not be allowed,
nor will essentially identical applications be reviewed by different
review committees.  Therefore, an application cannot be submitted in
response to this Program Announcement which is essentially identical to
one that has already been reviewed.  This does not preclude the
submission of substantial revisions of an application already reviewed,
but such application must include an "Introduction" addressing the
previous critique.
 
Applications will be evaluated for scientific and technical merit by the
Genome Research Review Committee (GRRC).  Review criteria include the
following:  overall scientific and didactic merit and need for the
course; potential effectiveness of the course in disseminating
information and new technological approaches/developments applicable to
furthering the goals of the Human Genome Program; quality of the course
content and adequacy of the syllabus; training, experience, and research
competence of the faculty; criteria for selecting participants and those
who may receive scholarships; plans for recruiting potential
participants and for publicizing the availability of courses to the
appropriate community of scholars and scientists; adequacy and
availability of the institution's facilities, including the library;
appropriateness of the requested budget for the proposed course.
 
Subsequent to GRRC review, the applications will be considered by the
National Advisory Council for Human Genome Research.
 
Funding decisions will be based on the recommendations of the GRRC and
the National Advisory Council for the Human Genome regarding scientific
merit and program relevance, respectively, the need for the particular
course relative to already available courses, and the availability of
funds.
 
METHOD OF APPLYING
 
Applications must be submitted on form PHS 398 (rev. 10/88) and will be
accepted at the standard application receipt dates. Application kits are
available in most institutional business offices and from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Bethesda, MD 20892; telephone (301)
496-7441.  The title and number of this announcement must be typed in
Item 2 on the face page of the application.
 
Applications will be accepted on the standard receipt dates for new
applications:  October 1, February 1 and June 1.  If applicants wish to
have the review of their applications expedited, they should contact
program staff listed at the end of this announcement for additional
information before developing the application.
 
The original and six copies of the application must be submitted to:
 
Grant Application Receipt Office
Division of Research Grants
Westwood Building, Room 240
National Institutes of Health
Bethesda, MD  20892**
Telephone:  (301) 496-7273
 
For more information regarding the program and expedited review of
applications, applicants may contact:
 
Bettie J. Graham, Ph.D.
Chief, Research Grants Branch
National Center for Human Genome Research
Building 38A, Room 612
National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 496-7531
E-mail address:  [email-masked]; [email-masked]
 
For information about PHS grants policy, applicants may contact:
 
Ms. Alice Thomas
Chief, Grants and Contracts Management Branch
National Center for Human Genome Research
Building 38A, Room 613
National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 402-0733
 
The program and grants management officials welcome the opportunity to
clarify any issues or questions related to this program announcement and
encourage written and telephone inquiries.
 
This program is described in the Catalog of Federal Domestic Assistance
No. 93.172.  Awards will be made under the authority of the Public
Health Service Act, Section 301 (Public Law 78-410, as amended 42 U.S.C.
241) and administered under PHS grants policies and Federal Regulations
42 CFR Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or to
Health System Agency review.
 
$$P2 END ***************************************************************
 
$$P3 BEGIN PA-91-89 ****************************************************
 
SPECIAL EMPHASIS RESEARCH CAREER AWARD IN GENOMIC RESEARCH
 
PA:  PA-91-89
 
P.T. 34; K.W. 1215018, 0755045, 1004017
 
National Center for Human Genome Research
 
The National Center for Human Genome Research (NCHGR) is soliciting
applications for Special Emphasis Research Career Awards (SERCA) from
eligible institutions to support highly qualified scientists seeking
careers in interdisciplinary genomic research.  This SERCA is intended
to foster the career development of individuals with expertise in
scientific disciplines that would further technological developments
critical to the success of the Human Genome Program.
 
BACKGROUND